Advaxis, Inc. (ADXS) Reports Two Executive Promotions, Updates on 2013 Annual Meeting of Stockholder
Advaxis, a biotech company developing the next generation of immunotherapies for cancer and infectious diseases, today said its board of directors has elected Dr. Robert Petit, currently vice president of Advaxis’ Clinical Operations and Medical Affairs, to the position of chief scientific officer. In addition, the company named Daniel J. O’Connor, currently senior vice president and chief legal and business development officer, to the position of executive vice president.
The promotions, effective May 3, 2013, reflect the men’s performance in the past and expected roles in assisting Advaxis in its future growth initiatives.
“The excellent contributions Robert and Dan have made to Advaxis have led to the board’s decision to elevate their status within the company,” Thomas A. Moore, chairman and CEO of Advaxis stated in the press release. “We look forward to working with our skilled and highly experienced leadership team during the next stage of development at Advaxis.”
Advaxis will hold its Annual Meeting of Stockholders June 5, 2013, at 10 a.m., Eastern Daylight Time, at the Princeton Marriott, 100 College Road East, Princeton, New Jersey 08540. Stockholders of record of the company’s common stock at the close of business April 15, 2013, are entitled to receive notice of, and to vote at, this year’s meeting.
For more information visit www.advaxis.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com